Skadden represented pharmaceutical manufacturer Biogen Inc. in its successful resolution of a U.S. Department of Justice civil investigation and underlying False Claims Act qui tam action concerning the company’s donations to charitable patient assistance programs. Biogen is the 12th company to resolve these allegations in the industrywide investigation, with the government requiring the majority of those companies to enter into a five-year corporate integrity agreement (CIA) with the Department of Health and Human Services Office of Inspector General. The successful resolution of the matter includes a payment of $22 million and does not require the company to admit any wrongdoing or enter into a CIA.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates